Literature DB >> 19276356

FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus.

Runhua Liu1, Lizhong Wang, Guoyun Chen, Hiroto Katoh, Chong Chen, Yang Liu, Pan Zheng.   

Abstract

p21 loss has been implicated in conferring oncogenic activity to known tumor suppressor gene KLF4 and cancer drug tamoxifen. Regulators of p21, therefore, play critical roles in tumorigenesis. Here, we report that X-linked tumor suppressor FOXP3 is essential for p21 expression in normal epithelia and that lack of FOXP3 is associated with p21 down-regulation in breast cancer samples. A specific FOXP3 binding site in the intron 1 is essential for p21 induction by FOXP3. FOXP3 specifically inhibited binding of histone deacetylase 2 (HDAC2) and HDAC4 to the site and increased local histone H3 acetylation. Short hairpin RNA silencing of either HDAC2 or HDAC4 is sufficient to induce p21 expression. Our data provides a novel mechanism for transcription activation by FOXP3 and a genetic mechanism for lack of p21 in a large proportion of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276356      PMCID: PMC2715174          DOI: 10.1158/0008-5472.CAN-08-3717

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination.

Authors:  M K Mateyak; A J Obaya; S Adachi; J M Sedivy
Journal:  Cell Growth Differ       Date:  1997-10

Review 2.  Five years on the wings of fork head.

Authors:  E Kaufmann; W Knöchel
Journal:  Mech Dev       Date:  1996-06       Impact factor: 1.882

3.  Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.

Authors:  K Somasundaram; H Zhang; Y X Zeng; Y Houvras; Y Peng; H Zhang; G S Wu; J D Licht; B L Weber; W S El-Deiry
Journal:  Nature       Date:  1997-09-11       Impact factor: 49.962

4.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

5.  Complex organization of CTF/NF-I, C/EBP, and HNF3 binding sites within the promoter of the liver-specific vitellogenin gene.

Authors:  J R Cardinaux; S Chapel; W Wahli
Journal:  J Biol Chem       Date:  1994-12-30       Impact factor: 5.157

6.  p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein.

Authors:  R J Slebos; M H Lee; B S Plunkett; T D Kessis; B O Williams; T Jacks; L Hedrick; M B Kastan; K R Cho
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

7.  p21 is a universal inhibitor of cyclin kinases.

Authors:  Y Xiong; G J Hannon; H Zhang; D Casso; R Kobayashi; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

8.  Absence of WAF1 mutations in a variety of human malignancies.

Authors:  M Shiohara; W S el-Deiry; M Wada; T Nakamaki; S Takeuchi; R Yang; D L Chen; B Vogelstein; H P Koeffler
Journal:  Blood       Date:  1994-12-01       Impact factor: 22.113

9.  Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells.

Authors:  K O Mitchell; W S El-Deiry
Journal:  Cell Growth Differ       Date:  1999-04

10.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.

Authors:  V Dulić; W K Kaufmann; S J Wilson; T D Tlsty; E Lees; J W Harper; S J Elledge; S I Reed
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

View more
  64 in total

1.  Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers.

Authors:  Weiquan Li; Lizhong Wang; Hiroto Katoh; Runhua Liu; Pan Zheng; Yang Liu
Journal:  Cancer Res       Date:  2011-01-28       Impact factor: 12.701

2.  X-linked tumor suppressors: perplexing inheritance, a unique therapeutic opportunity.

Authors:  Yang Liu; Lizhong Wang; Pan Zheng
Journal:  Trends Genet       Date:  2010-04-29       Impact factor: 11.639

3.  Foxp3 promoter polymorphism (rs3761548) in breast cancer progression: a study from India.

Authors:  Parveen Jahan; V R Vinish Ramachander; G Maruthi; S Nalini; K Prasanna Latha; T S R Murthy
Journal:  Tumour Biol       Date:  2013-12-13

Review 4.  FOXP3 as an X-linked tumor suppressor.

Authors:  Lizhong Wang; Runhua Liu; Mark Ribick; Pan Zheng; Yang Liu
Journal:  Discov Med       Date:  2010-10       Impact factor: 2.970

5.  Endogenous FOXP3 inhibits cell proliferation, migration and invasion in glioma cells.

Authors:  Biao Zhang; Yuchao Dou; Xinnv Xu; Xiuyu Wang; Bin Xu; Jixiang Du; Qiong Wang; Qingguo Li; Jinhuan Wang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 6.  Biological determinants of endocrine resistance in breast cancer.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

7.  IPEX Syndrome, FOXP3 and Cancer.

Authors:  Runhua Liu; Silin Li; Wei-Hsiung Yang; Lizhong Wang
Journal:  J Syndr       Date:  2013-06

Review 8.  Signalling through FOXP3 as an X-linked tumor suppressor.

Authors:  Hiroto Katoh; Pan Zheng; Yang Liu
Journal:  Int J Biochem Cell Biol       Date:  2010-08-01       Impact factor: 5.085

9.  Epigenetic mechanisms regulate stem cell expressed genes Pou5f1 and Gfra1 in a male germ cell line.

Authors:  Maren Godmann; Erin May; Sarah Kimmins
Journal:  PLoS One       Date:  2010-09-14       Impact factor: 3.240

Review 10.  HDAC4: mechanism of regulation and biological functions.

Authors:  Zhengke Wang; Gangjian Qin; Ting C Zhao
Journal:  Epigenomics       Date:  2014-02       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.